U.S. patent application number 14/299635 was filed with the patent office on 2014-11-27 for drug delivery management system.
This patent application is currently assigned to DDMS Holdings LLC. The applicant listed for this patent is DDMS Holdings LLC. Invention is credited to Louis M. Heidelberger, Mark A. Niemiec.
Application Number | 20140346224 14/299635 |
Document ID | / |
Family ID | 31977355 |
Filed Date | 2014-11-27 |
United States Patent
Application |
20140346224 |
Kind Code |
A1 |
Niemiec; Mark A. ; et
al. |
November 27, 2014 |
DRUG DELIVERY MANAGEMENT SYSTEM
Abstract
The present invention relates to assisting patients in the
taking of medication, and to assisting third parties in
accumulating information regarding patient medication intake. The
invention may be embodied a system including a portable medication
monitor used in association with an instrumented medication package
to provide intake data acquisition and patient support functions.
The system may further be connected to a computer or computer
network allowing information distribution between the medication
monitor and third parties, such as physicians or pharmacists.
Inventors: |
Niemiec; Mark A.; (Malvem,
PA) ; Heidelberger; Louis M.; (York, PA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
DDMS Holdings LLC |
Malvern |
PA |
US |
|
|
Assignee: |
DDMS Holdings LLC
Malvern
PA
|
Family ID: |
31977355 |
Appl. No.: |
14/299635 |
Filed: |
June 9, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13204951 |
Aug 8, 2011 |
|
|
|
14299635 |
|
|
|
|
11948478 |
Nov 30, 2007 |
8014232 |
|
|
13204951 |
|
|
|
|
11931863 |
Oct 31, 2007 |
7612662 |
|
|
11948478 |
|
|
|
|
11187727 |
Jul 22, 2005 |
7304913 |
|
|
11931863 |
|
|
|
|
10234022 |
Sep 3, 2002 |
6961285 |
|
|
11187727 |
|
|
|
|
09901475 |
Jul 9, 2001 |
6574166 |
|
|
10234022 |
|
|
|
|
09611582 |
Jul 7, 2000 |
6411567 |
|
|
09901475 |
|
|
|
|
Current U.S.
Class: |
235/376 ;
235/375; 235/377; 235/385 |
Current CPC
Class: |
H02M 7/003 20130101;
G08B 21/24 20130101; A61J 2200/30 20130101; H05K 1/0293 20130101;
A61J 7/0436 20150501; A61J 2200/72 20130101; G16H 20/13 20180101;
A61J 1/035 20130101; A61J 7/0481 20130101; G08B 13/1427 20130101;
H01H 3/141 20130101; G06Q 10/083 20130101; G06Q 10/087 20130101;
G16H 10/60 20180101; A61J 7/0454 20150501; A61J 2205/70 20130101;
A61B 5/0002 20130101; G08B 21/0261 20130101; G16H 40/20 20180101;
G16H 40/67 20180101; A61J 2205/60 20130101 |
Class at
Publication: |
235/376 ;
235/385; 235/375; 235/377 |
International
Class: |
G06Q 50/22 20060101
G06Q050/22; G06Q 10/08 20060101 G06Q010/08 |
Claims
1-20. (canceled)
21. A drug management system, comprising; a plurality of
instrumented medication packages, each having a unique package
identifier, each of the instrumented medication packages having a
transponder configured to receive a trigger signal and transmit a
response signal in response to the trigger signal, the response
signal being based at least in part on the unique package
identifier; and a monitor configured to transmit the trigger signal
to the plurality of instrumented medication packages and to receive
the responses from the plurality of instrumented medical packages,
wherein the monitor is configured to parse the responses received
from the plurality of instrumented medical packages to confirm the
presence of each instrumented medication package based upon the
unique package identifier thereof.
22. A drug management system as in claim 21, further including a
plurality of portals at which a monitor is located, wherein the
presence of the plurality of instrumented medication packages is
determined at each portal.
23. A drug management system as in claim 21, wherein each
instrumented medication package contains a sensor to monitor
medication contained in each instrumented medication package.
24. A drug management system as in claim 21, wherein, a plurality
of medications is present in each instrumented medication package
and the sensor can monitor each medication.
25. A drug management system as in claim 34, wherein the sensor
monitors, for each medication, a condition of the medication, the
condition including one or more of the following factors: presence,
integrity, temperature, humidity, and light exposure.
26. A drug management system as in claim 25, wherein the condition
of each medication of each instrumented medication package is
stored in the instrumented medical packages and transmitted to the
monitor upon receipt of the trigger signal.
27. A drug management system as in claim 26, wherein the condition
is communicated to one or more stakeholders selected from a group
consisting of: pharmacies, doctors, nurses, patients, back office
billers, co-packers, drag manufacturers, and insurance
companies.
28. A drug management system as in claim 21, wherein said package
identifier comprises a package identification code identifying an
individual responding package.
29. A drug management system as in claim 21, wherein said package
identifier comprises a package identification code identifying
production information associated with the medication contained in
said instrumented medication package.
30. A drug management system as in claim 21, wherein said package
identifier comprises a package identification code identifying an
expiration date associated with the medication contained in said
instrumented medication package.
31. A drug management system as in claim 21, wherein at least one
of the monitor and the plurality of instrumented medication
packages comprises active radio frequency identification circuitry
and a power supply.
32. A drug management system as in claim 31, wherein each of the
plurality of instrumented medication packages bather comprises
means for activating said active radio frequency identification
circuitry.
33. A drug management system as in claim 32, wherein each of the
plurality of instrumented medication packages further comprises
means for deactivating said power supply.
34. A multi-component drug management system comprising: a
plurality of instrumented medication packages, each instrumented
medical package having a unique package identifier and comprising
network connection circuitry for communicably connecting said
instrumented medical package with one or more components of said
drug management system, wherein the unique package identifier is
communicated to at least one component of said drug management
system.
35. A multi-component drug management system as in claim 34,
further including a computer and software for monitoring each
instrumented medical package.
36. A multi-component drug management system as in claim 34,
wherein said network connection circuitry is wireless.
37. A multi-component drug monitoring system as in claim 36,
wherein the wireless connection device is a PDA.
38. A multi-component drug monitoring device as in claim 34,
further including as a component, a PDA, wherein the network
connection circuitry enables communication of the instrumented
medical package with the PDA.
39. A multi-component drug management system as in claim 35,
wherein said software comprises instructions which when executed
attempts communication with the computer via said network
connection circuitry in accordance with a predetermined schedule,
said communication attempts being repeated until said communication
is successful.
40. A multi-component drug management system as in claim 34,
wherein communication comprises information associated with the
accessing of medication contained in the instrumented medication
package.
41. A multi-component drug management system as in claim 34,
wherein the communication comprises time information associated
with the accessing of medication contained in the instrumented
medication package.
42. A multi-component drug management system as in claim 34,
wherein, the communication comprises dosage information associated
with the accessing of medication contained in the instrumented
medication package.
43. A multi-component drug management system as in claim 34,
wherein the communication comprises patient information associated
with the accessing of medication contained in the instrumented
medication package.
44. A multi-component drug management system as in claim 34,
wherein the communication comprises medication information
associated with the accessing of medication contained in the
instrumented medication package.
45. A multi-component drug management system as in claim 35,
wherein the at least one computer verifies the time, the dosage,
the patient and the medication information and transmits said
information to at least one other component of the drug management
system.
46. A multi-component drag management system as in claim 45,
wherein a stakeholder may access the time, dosage, patient and
medication information.
47. A multi-component drug management system as in claim 35,
wherein the computer periodically monitors the instrumented medical
packages to determine the conditions of each instrumented medical
package.
48. A multi-component drag management system as in claim 34,
wherein the instrumented medical packages are transported
throughout at least a portion of the distribution chain of a drug
management system and the condition of instrumented medical
packages are monitored throughout said transportation.
49. A multi-component inventory management system comprising: a
plurality of instrumented packages, each instrumented package
containing product and each having a unique product identifier,
network connection, circuitry configured to connect said
instrumented package with a component of the inventory management
system and to receive a location-based signal, wherein the unique
product identifier is communicated to the at least one component of
the inventory management system when the location-based signal is
no longer received.
Description
[0001] This application is a continuation of U.S. patent
application Ser. No. 13/204,951, filed Aug. 8, 2011, which is a
continuation of U.S. patent application Ser. No. 11/948,478, filed
Nov. 30, 2007, which is a continuation of U.S. patent application
Ser. No. 11/931,863, filed Oct. 31, 2007, which is a continuation
of U.S. patent application Ser. No. 11/187,727, which is a
divisional of U.S. Pat. No. 6,961,285 (U.S. patent application Ser.
No. 10/234,022), riled Sep. 3, 2002, which is a
continuation-in-part of U.S. Pat. No. 6,574,166 (U.S. patent
application Ser. No. 09/901,475), filed by Jul. 9, 2001, which is a
continuation-in-part of U.S. Pat. No. 6,411,567 (U.S. patent
application Ser. No. 09/611,582), filed Jul. 7, 2000, the entire
contents of each of which are incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The present invention pertains to the accumulation and
dissemination of information associated with the taking of
medications, and more particularly to the acquisition,
dissemination, and utilization, of information obtained through
implementation of an instrumented medication package.
BACKGROUND OF THE INVENTION
[0003] The explosive developments in medical treatment relating to
drugs have created a costly and high risk drug management
environment. A 1995 study published in the "Archives of Internal
Medicine" estimates that $76 billion is spent each year in the U.S.
on extra doctor visits and hospitalization because people do not
take their medication properly. In addition, a 1999 study by the
National Academy of Science, Institute of Medicine, describes
errors made in the hospitals which threaten patient's health. The
study estimated that 98,000 patients die each year because of
medical mistakes. Prescription drug errors are one of the major
areas where mistakes are made.
[0004] Unit-dose blister type packaging for prescription drugs is
one of the fastest growing package formats and is projected to be
at 40% penetration, in the U.S. market by 2003. Blister packages
are already the dominant prescription drug package format in Europe
with 85% penetration. Some of the reasons behind this growing use
of blister packaging are; (i) product integrity being maintained
throughout out the drag life cycle, (ii) better product protection
to insure quality and efficacy of the drug, (iii) better tamper
evidencing and child resistance, and (iv) improved patient
compliance in that unit-dose blister packaging gives patients a
clearly marked individual dosage.
[0005] The ability to obtain, data regarding the usage of
medications through a blister pack containing devices for
monitoring the accessing of individual containments within the
packaging is described in several references, including Applicant's
U.S. patent application Ser. No. 09/611,582. These references teach
monitoring the accessing of individual containments to determine
whether and when, a medication was taken, in order to accumulate
information regaining the medication intake.
[0006] The taking of medications has become a central aspect of
life. Individuals may take over the counter or prescription
medications for a wide range of ailments. The effectiveness of the
medications may be dependant on a patient's punctuality of
application or ingestion (hereinafter referred to genetically as
"medication intake") of the medication at issue.
[0007] The punctuality with which a patient takes medication may
affect every entity in the health care chain. The patient taking
the medication on time increases the likelihood that the medication
will be effective, thus reducing disadvantages associated with the
medical condition for which the medication, is being taken. These
disadvantages may include work time lost due to the condition as
well as patient-discomfort associated with the condition the
improved effectiveness associated with timely medication also
benefits physicians, by reducing the likelihood that the medication
will be unsuccessful in resolving the condition, thus reducing the
likelihood that additional, visits are required to resolve the
condition. Increased effectiveness associated with timely
medication may also reduce the total amount of medication needed to
be taken by a patient, thus reducing the cost, of resolving the
medical condition, such that expenses to health care insurers are
reduced.
[0008] In order to assess the compliance of a patient taking
medication according to an intake schedule, instrumented medication
packages have been developed. These packages incorporate a method
of identifying the dispensation of medication from the package. The
inclusion of a clock allows the information to be correlated to
time. Early efforts used some form of memory associated with the
package to store dispensation time information for later
downloading, such as when the package was returned, to a pharmacy
or other download-capable site. The necessity of returning the
package to a specific location had several drawbacks, including the
hack of incentive for a patient to return the package unless
another prescription was to fee picked up. Additionally, the
dispensation information would not be available to anyone in the
chain of entities involved in the treatment of the patient (the
chain may include, but is not limited to, a doctor, pharmacist
insurer, medication manufacturer, the patient him or herself, other
caregivers, or anyone else involved in the treatment of the
patient) until after the package had been returned, and any data
downloaded.
[0009] Applicant's earlier patent application disclosed the use of
a network of receivers for receiving information from instrumented
medication packages. One embodiment included the use of receivers
located in hospital rooms to allow in-hospital monitoring of
medication intake. Another embodiment utilized receivers located at
diverse locations, including pharmacies and patient residences, to
provide broader coverage for acquiring information from
instrumented medication packages. Additional embodiments included
capabilities for monitoring additional conditions associated with
the taking of medication, including the conditions of storage of
the instrumented medication package itself.
SUMMARY OF THE INVENTION
[0010] The present invention is a system and process for assisting
patients with medication compliance. The system combines an
instrumented medication package with a portable medication monitor
to provide support to the patient in taking medication as directed.
The system and process may additionally be communicably connected
to a third party computer or computer network to allow third
parties to access information on the medication monitor or to
provide information to the patient via the medication monitor.
Additionally, the medication monitor, when connected to a third
party computer or computer network may be used to collect data
regarding medication compliance for use in determining the efficacy
of medications being taken by the patient.
[0011] In one form, the present invention may be embodied in a
medication monitoring system which includes an instrumented
medication package. The instrumented medication may have a
plurality of medication containments, each medication containments
having an closure incorporating a severable connector. The
instrumented medication package may also include an instrumented
medication package receiver and an instrumented medication package
transmitter. The instrumented medication package receiver may be
used for receiving trigger signals, and the instrumented medication
package transmitter may be used for transmitting information
identifying the condition of the severable connectors. The system
may also include a medication monitor. The medication, monitor may
nave a medication monitor transmitter and a medication monitor
receiver. The medication monitor transmitter may be used for
transmitting a trigger signal, while the medication monitor
receiver may be used, for receiving information transmitted by an
instrumented medication package transmitter.
[0012] In another form, the present invention may be embodied in an
instrumented medication package having a plurality of medication
containments. The medication containments each may have a closure
having a severable connector. The instrumented medication package
may further have an instrumented medication package transponder.
The instrumented medication package transponder may be used for
receiving trigger signals, and transmitting a response signal in
response to the trigger signals. The instrumented medication
transponder may further include passive radio frequency
identification circuitry. The passive radio frequency
identification circuitry may comprise circuitry which modifies a
response signal generated by the passive radio frequency
identification circuitry, said response signal utilizing the energy
of the trigger signal.
[0013] In a still further form, the present invention may be
embodied in a portable medication monitor having a general purpose
computing circuitry, and an instrumented medication package
transceiver. The instrumented medication package transceiver may
include a transmitter and a receiver for transmitting to and
receiving signals from an instrumented medication package. The
portable medication monitor may farther have a network connection,
for communicably connecting the portable medication monitor to at
least one remote computer. The portable medication monitor may also
include software for monitoring instrumented medication packages
which may be associated with the portable medication monitor.
[0014] In a still further form, the present invention may be
embodied in a method for monitoring medication intake. The method
may include providing an instrumented medication package and a
medication monitor. A trigger signal may be emitted from the
medication monitor and received by the instrumented medication
package. When the trigger signal is received, the instrumented
medication package may transmit information identifying foe
condition of severable connectors. The transmitted information may
be received at the portable medication, monitor, which may then
forward the information to a remote computer via a network
connection.
BRIEF DESCRIPTION OF THE FIGURES
[0015] FIG. 1 illustrates an instrumented medication package
associated with a medication, monitor.
[0016] FIG. 2 illustrates an instrumented medication package
associated, with a medication monitor implemented within, a health
care network according to the present invention.
[0017] FIG. 3 shows a process flowchart illustrating a process of
using a medication monitor in association with an instrumented
medication package according to the present invention.
[0018] FIG. 4 shows a hybrid, passive and active circuitry
instrumented medication package associated with monitoring
capabilities according to the present invention.
[0019] FIG. 5 shows a hybrid passive and active circuitry
instrumented medication package implemented in a pharmacy
environment.
[0020] FIGS. 6A, 6B, 6C and 6D show a process flowchart
illustrating a process of using a hybrid passive and active
instrumented medication package according to the present
invention.
DETAILED DESCRIPTION OF THE INVENTION
[0021] In FIG. 1, wherein like numbers represent like elements,
there is shown an illustration of the components of a medication
monitoring system 100 according to the present invention. The
system may have an instrumented medication package 102 and a
medication monitor 104 associated them with. The instrumented
medication package 102 includes a transmitter 106 capable of
transferring information associated with the instrumented
medication package 102 to the medication monitor 104. The
medication monitor 104 includes a receiver 108 for receiving
information from the instrumented medication package 102.
[0022] The medication monitor 104 is preferably portable, such that
the medication monitor 104 may accompany a patient (not shown) as
the patient travels. The medication monitor 104 may include a
processor 110 which provides functionality for the medication
monitor 104, such as in conjunction with, operating instructions
112 or a computer program for communicating with the instrumented
medication package 102 and handling data received from the
instrumented medication package 102. The medication, monitor 104
may also be provided with a display 114 such that a patient may
receive information or reminders regarding medication to be taken.
The display 114 may be aural tactile, or visual, or a combination
thereof, snob that reminders can be provided to a patient, such as
a reminder that a dose of medication is due to be taken. The
medication monitor may also include memory 110 to allow the
medication monitor 104 to be used as a data accumulator, such that
information retrieved from an instrumented medication package 102
may be removed from the instrumented medication package 102 once
provided to the medication monitor 104, allowing reduced
requirements for data storage integral to the instrumented
medication package 102.
[0023] The medication monitor 104 may also be provided with
functionality allowing information, associated with the
instrumented medication package 102 to be displayed for the patient
taking the medication. The use of severable conductors 118 in
association with medication containments 120 allows the detection
of when a patient, accesses medication (not shown). For example, a
patient unsure of whether they took required medication on time
would be able to review the times at which medication containments
120 were accessed, and compare this information with an intake
schedule identifying when a dose was supposed to have been taken.
Furthermore, the medication monitor 104 may be provided with
functionality to allow a dosing schedule to entered into and
displayed on the medication monitor 104, such, that the
patient-would be easily able to determine when a dose should have
been, taken, as well as whether a dose was accessed at the
requisite time.
[0024] The medication monitor 104 may also be provided with a
transmitter 122 to allow the use of a transmission to trigger to be
received by a instrumented medication package receiver 124 an
information transfer from the instrumented medication package 102.
The instrumented medication package 102 may utilise radio frequency
identification technology to provide data transmission, from the
instrumented medication 102 package to the medication, monitor 104.
Radio frequency identification (RFID) technologies function as
transponders, such that receipt of a trigger signal causes the RFID
to respond with an identification transmission. The identification
transmission may include data to be transmitted from the
instrumented medication package 102 to the medication monitor 104,
such as times at which severable conductors 118 were severed, or
other information stored by the instrumented medication package
108.
[0025] Several methods for generating and types of trigger signals
may be implemented. The use of radio frequency signals allows a
triggering signal unique to the instrumented, medication package
102 to be utilized. The use of the unique trigger signal reduces
the likelihood that third parties would be able to generate a
trigger signal to receive information from a instrumented
medication package. The unique trigger signal may be associated
with, the actual medication package 102 itself, such that entry of
an identifier into the medication monitor 104 may allow the
medication monitor 104 to be able to generate a trigger signal for
the instrumented medical package 102 for which an identifier has
been provided.
[0026] The medication monitor 104 may also be provided with
functionality to allow the medication monitor 104 to receive
information from more than one instrumented medication package
(102b, 102c) concurrently. As more than one medication may be
required to be taken by a patient during a time period, the ability
of the medication monitor 104 to acquire data and track multiple
medications provides both an efficiency with regards to the
acquisition of information, as well as a convenience to the
patient, i.e., that a single medication monitor 104 may be used to
support the taking of multiple medications.
[0027] In order to allow a single medication monitor 104 to receive
information from more than one instrumented medication package
(102, 102b, 102c), a method of deconflicting triggering and
reception of information from the instrumented medication packaging
may be implemented. Where active RFID's are used, one solution may
be to impose a communications protocol allowing information to be
transmitted both from the instrumented medication package 102 to
the medication monitor 104, and from the medication monitor 104 to
the instrumented medication package 102. The use of two way
communications also allows additional communications security to be
enable between the medication monitor 104 and an instrumented
medication package 102, such drat privacy issues regarding the
medication and its usage may be maintained. The imposition of a
protocol for such transmissions may also allow a single medication
monitor 104 to be used with instrumented medication packages from
various suppliers, such that a patient would not be required to
maintain multiple medication monitors to allow the concurrent
taking of multiple medications when those medications are from more
than one supplier.
[0028] Active RFIDs typically use a triggered response form of two
way communication to allow the conservation of power within the
RFID. By only transmitting information in response to a trigger
signal, power can be conserved by avoiding unnecessary
transmissions. The use of trigger common to multiple devices,
however, may allow an instrumented medication package 102 to
transmit a response whenever a trigger signal is received, whether
or not the trigger signal was intended for the instrumented
medication package 102. Random triggering may also raise battery
hie concerns, especially if unintended triggers are frequently
received. Common trigger signals also make it more likely that
third parties can successfully trigger information transmissions
from an instrumented medication package 102. Where health care is
involved, privacy issues raise concerns regarding the ability of
third parties to access patient care information, in the case of a
medicated instrumentation package 102, information transmitted by a
transmitter associated with the package may provide information to
third parties. By limiting the validity of a trigger signal to a
specific signal, such as the address identifying a specific
instrumented medication package 102, the ability of third parties
to trigger the transmission of information from an instrumented
medication package 102 may be sufficiently curtailable to avoid
privacy issues. The specific signal used may be implemented by
providing to the medication monitor 104 an identifying number for
the instrumented medication package 102, such as an identifier
containing both random and non-random portions. For example, a
portion of an identifier may serve to identify the manufacturer of
the medication, while another portion contains a random number
associated with the particular instrumented medication package 102.
By implementing a manufacturer identifier, individual manufacturers
may be able to implement the random number portion of the
identifier without fear of duplicating an identifier front a
different manufacturer, such as would be possible, albeit unlikely,
if only a random number were used.
[0029] The processor 126 of the instrumented medication package 102
may monitor transmissions received by the instrumented medication
package receiver 104 in order to detect receipt of a correct
trigger. Receipt of a signal by the receiver 124 may trigger the
instrumented medication package processor 126 to attempt to decode
the signal to determine whether the signal contains the correct
information. If the signal contains the correct trigger
information, the processor 126 may trigger a transmission of
information from the instrumented medication package 102, such as a
list of medication cell accesses since a last transmission, or over
a given period of time.
[0030] The incorporation of a unique identity associated with the
trigger signal may also be used as part of an encryption algorithm,
such that data transmitted from an instrumented medication package
102 may utilise the random portion of the package identifier as a
seed for an encryption routine. Thus, the random number would need
to be known in order to trigger a transmissions as well as to
understand the meaning of the resultant transmission.
[0031] In one form, the medication monitor 102 may be implemented
by the provision of specific functionality to a personal digital
assistant (PDA). PDA's typically include the ability to accept add
on modules, with control ox the module being provided by, the
control circuitry of the PDA. In such an embodiment, the general
functionality of the PDA may be utilized to provide the display and
interface capabilities. Display functions could, be accomplished
through any display capable of generating a signal which can be
sensed by a patient, such as a visual display, an auditory display
(buzzer or other tone), or a vibratory display. Taste and smell
displays are also feasible, although present technology limits the
cost efficiency with which such displays can be generated.
[0032] The PDA may be provided with a transmitter/receiver modem
capable of generating a trigger signal and receiving a responding
transmission from an instrumented medication package. Although a
radio frequency (RF) signal is discussed in the present
implementation, light transmission, such as an infrared signal
commonly used with items such as television remotes and
calculators, may also be used, however such a signal may be limited
in effectiveness due to its line of sight nature. An RF
communications path using a frequency in common with pagers or cell
phones could be susceptible to interference from cell phones and
pagers being operated near the medication monitor 104 and
instrumented medication package 102, especially if low transmission
strengths are utilized to conserve power, or limit the ranges at
which the signals could be received.
[0033] Accordingly, use of a frequency range dedicated to
medication monitors may improve the performance of the monitors by
avoiding interference from other transmitters. Multiple sets of
medication monitors 104 and instrumented medication packages 102
operating in the same area may be problematic, in that
transmissions associated with the individual medication monitors
104 and instrumented medication packages 102 could interfere with
each other. In the absence of some other method of deconflicting
signals, limiting the transmission power of the individual
medication monitors 104 and instrumented medication packages 102
limits the range at which individual components would interfere
with each other. Although not a perfect solution, utilization of
power limited transmissions allows a single frequency to be used
for instrumented medication packages 102, such that the cost of the
transmitters 106 on the instrumented medication package 102, which
may be disposable, may be kept at a minimum. Use of a common
frequency furthermore increases the commonality of the medication
monitor 104, such that the cost impediment to procuring a
medication monitor 104 may be minimized.
[0034] Alternately, other methods of deconflicting the
transmissions may be implemented. Where instrumented medication
packages 102 can have the capability of transmitting at different
frequencies, frequencies may be selected, based on criteria likely
to avoid generating conflicting transmissions. For example, a
frequency could be selected based on the dale of birth and first
initial of a patient. The limitation to such an algorithm is the
range of frequencies that an instrumented medication package 102
must be capable of transmitting over. The frequency range is a
function of the frequency difference between two signal frequencies
that is required to avoid intolerable interference between
transmissions at the signal frequencies. Thus, the range may be
determined by the number of signal frequencies to be implemented
multiplied by the frequency difference. A tendency exists that the
broader the range required of a transmitter 106, the higher the
cost of the transmitter. Thus, minimizing the requited range may
allow reduced costs for the transmitter 106 associated with an
instrumented medication package 102.
[0035] Although the description to this point suggests the
association of a single patient with a medication, monitor 104, a
single medication monitor 104 may be utilized to monitor multiple
patients concurrently. Tire ability to concurrently monitor
multiple patients could be implemented simply by association, of a
patient identification with an instrumented medication package 102,
102b, 102c, when the instrumented medication package 102 was
identified to the medication monitor 104. For instance, one person
could monitor both his or her own medication concurrently with
monitoring an instrumented medication package 102 containing
medicine prescribed for a significant other, parent, or child.
Alternately, multiple, patient monitoring could be implemented to
allow a nurse on a ward to ensure that medications for multiple
patients were accessed correctly. These implementations are
discussed further below.
[0036] As generally illustrated in FIG. 2, the medication monitor
104 may be further provided, with a remote communications
capability, such as a capability to communicate with a remote
computer 200 via a communications path 202. The communications path
may be a wireless path, such as a satellite communications path 204
or a cellular transmission network 206 used with cell phones and/or
other wireless handheld devices. Alternately, the communications
path may be a publicly switched telephone network 208 (hereafter
referred to as a "PSTN") path, or a pre-wired communications path,
such as a connection to the internet or other form of network
connection. Such access may be gained by connecting the medication
monitor 104 to a docking station 222.
[0037] The remote computer 200 may be a single computer or one of
several computers in a network. The remote computer 200 may be
communicably connected to the medication monitor 104 when a
communications path 200 is established through one or more other
computers, servers, or router. The remote computer 200 may contain
a database 210 storing information associated with the medication
taken by one or more patients. The remote computer 200 may also
include a network access 212, such, that third parties may access
the stored data via a network. Additionally, the remote computer
may be provided with e-mail or fax transmission capability, such
that automated notices may be forwarded to recipients as
indicated.
[0038] The third party access to the network may include access to
the system by a physician through a physician's terminal 214, such
that a physician could monitor the punctuality of a patient in
accessing medication, or in determining what medication has been
prescribed to a patient, such as what may occur when multiple
physicians are responsible for the care of a single patient.
Information concerning medications prescribed to a patient could
include medications prescribed, as well as medication actually
associated with, a medication monitor 104, such that a physician
could determine not only what medication was prescribed, bat the
status of a patient in completing a course of medication. This
information could allow a physician to tailor a prescription to
work best in a situation where drug interactions could adversely
affect the efficacy of a particular medication.
[0039] A hospital terminal 216 could, also be provided, to allow a
hospital to determine present medication in the event that a
patient was brought to an emergency room. Again, access to
information identifying medications taken, and when last taken,
would allow the hospital, to more effectively treat the
patient.
[0040] A pharmaceutical manufacturer access 218 could be provided
to allow the pharmaceutical manufacturer to accumulate ongoing
efficacy information regarding its products, such as information
concerning the timeliness with which patients actually take
medication, as well as whether courses of medication were
completed, or not completed.
[0041] A health insurer access 220 could also be provided to allow
an insurance carrier to better track medications dispensed to a
patient. The health insurer access, in conjunction with a pharmacy
access 222, could be implemented to allow prescriptions provided to
the system through a physician access to be dispensed via the
pharmacy access 222, and accounted for by the pharmacy access and
health insurer accesses automatically, reducing the administrative
overhead associated with the dispensation process. Further, where
two way communications between the medication monitor 104 and the
remote computer 200 have been implemented, identification
information associated with a particular instrumented medication
package 102 may be transferred directly from a pharmacy access 222
to a medication monitor 104 via the remote computer 200, removing
the necessity of a patient entering data into the medication
monitor 104 to associate a specific instrumented medication package
102 with the monitor 104.
[0042] FIG. 3 illustrates a simple process embodying the present
invention. An instrumented medication package 102 may be associated
with the medication monitor 104. Association 302 informs the
medication monitor 104 of the need to start monitoring information
from the instrumented medication package 102. The association 302
step may include the prevision of relevant information to the
medication monitor 104, such as any identifiers for the
instrumented medication package 102 needed to trigger a data
transmission from the instrumented medication package. Additional
information which may be associated is discussed further below.
[0043] Once the medication monitor 104 has been associated 302 with
the instrumented medication package 102, the medication monitor 104
may begin monitoring the instrumented medication package 102 for
transmitted information. The instrumented medication package 102
may be provided with instructions to periodically transmit data,
such as in accordance with a predetermined schedule, or in response
to the acquisition of data. Alternately, the instrumented
medication package 102 may be provided with instructions to
transmit acquired data in response to receipt of a valid trigger
signal.
[0044] The use of a trigger signal as a means for irrigating a data
transmission from an instrumented medication package 102 may have
several advantages. Where the instrumented medication package 102
transmits only in response to a trigger signal, power may be saved
in the instrumented medication package 102 by the avoidance of
transmissions when a medication monitor 104 is out of range of the
instrumented medication package 102 transmitter 106. In order to
verily range, the instrumented medication package 102 may be
provided with discriminating circuitry to test the strength of a
received signal. Signals below a threshold would be considered
"out-of-range", such that the instrumented medication package 102
would not transmit data in response to receipt of an otherwise
valid trigger, A range test could be important, especially where a
medication monitor 104 incorporated a transmitter 122 having
greater capabilities than the transmitter 106 of the instrumented
medication package 102, causing an ability for the instrumented
medication package 102 to receive signals transmitted by die
medication monitor 104, while at the same time the medication
monitor 104 would be unable to receive signals transmitted from the
instrumented medication package 102. Seek a signal strength test
could be implemented as part of a trigger validation routine, such
as where a unique identifier for the instrumented medication
package 102 is implemented as a trigger validation method.
[0045] The schedule at which the medication monitor 104 triggers a
transmission may be based on various patterns. In a simple
schedule, the medication monitor 104 could attempt to trigger a
transmission at a fixed frequency, such as once an hour. More
complex schedules may be based on the dosing schedule of the
particular medication, on a schedule based on the last successful
triggering of a transmission, or based on a schedule provided by a
patient.
[0046] For example, a patient could be prescribed a medication to
be taken three times a day, two doses at each time. The patient,
could decide to take the medication at 6:00 AM, 3:00 PM, and 10:00
FM, in order to squeeze the three dosages into waking hours. The
patient could provide the schedule to the medication monitor 104,
which could then schedule attempts to trigger a transmission 1/2
hour after each, scheduled time. Should a trigger attempt fail, the
medication monitor 104 could be programmed to either re-attempt to
trigger a transmission at a certain amount of time after the failed
trigger attempt, or could be programmed to generate an alarm
requiring the patient to manually verify that a scheduled dosage
had been taken. Alternately, if the medication monitor 104 was able
to successfully trigger a transmission, and the transmission did
not indicate that medication had been accessed, the medication
monitor 104 could generate an alarm to warn a patient that a
scheduled dosage had been missed.
[0047] Monitoring of an instrumented medication, package 102, as
illustrated, could be implemented by providing a schedule to a
medication monitor 104. The provided schedule could be based on
information provided with a basic monitoring program used by the
medication monitor. Alternately, the schedule could be provided via
a remote computer 200, or entered directly into the medication
monitor 104 when an instrumented medication package 102 is
associated with the medication monitor 104. The medication monitor
104 would then test 304 the schedule to determine whether it was
the correct time to request a transmission from the instrumented
medication package 102. Such a determination would be dependant
upon the test schedule provided. For example, if the schedule
instructed that a transmission be generated every hour, the
medication monitor 104 could check a time counter to determine
whether an hour had elapsed since the last trigger transmission.
Alternately, where the schedule were based on generating a trigger
transmission at a specific time, the medication monitor could
compare the scheduled time with the time shown by an internal
clock, and determine to generate a trigger transmission when the
scheduled time and clock time worn the same.
[0048] If it were determined 300 that the schedule indicated that a
trigger transmission should be transmitted, the medication monitor
could transmit 308 a trigger transmission. The instrumented
medication package 102 would receive 310 the trigger transmission,
and respond by transmitting 312 information to the medication
monitor 104. The information could be as simple as an
acknowledgment of receipt of the trigger signal, signifying an
absence of relevant data to be reported, or a report merely
informing the medication monitor which medication containment cells
had been accessed. The transmission could also inform the
medication monitor of other information, suck as times when
containment cells were accessed, or other parameters monitored by
the instrumented medication package.
[0049] The transmitted information would be received 314 by the
medication monitor, which could store the information, or
disseminate the information to a remote computer 200, as indicated
by the internal operating instructions 112 of the medication
monitor 104. The medication monitor 104 could then return to
waiting for the next scheduled trigger transmission time.
[0050] Concurrently with monitoring an associated instrumented
medication package, the medication monitor 104 could monitor for
data access requests forwarded by the remote computer. If a data
access request were received 316, the medication, monitor 104 could
report 320 the requested data to the remote computer, and continue
monitoring the instrumented medication package according to the
schedule.
Alternate Embodiments
[0051] The systems and method described above include functionality
providing benefits beyond the illustrated association between a
patient and a medication monitor 104. As noted, a medication
monitor may be tasked with monitoring medication for more than one
patient. A medication monitor 104 may also be associated with
multiple patients, such as a medication monitor 104 being
associated with a family having multiple members, such that one
member could track medication usage of multiple members of the
family, such as a mother tracking a teen-aged child's taking of a
antibiotic for an ear infection, while simultaneously tracking her
husbands taking of a medication for heartburn.
[0052] Alternately, the medication monitor 104 could be associated
with a single medical care provider, such as a nurse, who is
responsible for medication regimens for a group of patients.
Implementation of communications path 202 between the remote
computer 200 and the medication monitor 104 would allow the remote
computer 200 to monitor medications accessed by the nurse for
dispensation to patients, such that the medications accessed by the
nurse could, be monitored in a sufficiently rapid fashion to allow
errors in accessing medication to be caught before the medication
was delivered to patients. Such a communications path could be a
direct connection between the medication monitor 104 and the remote
computer 200, such as a wireless network connection. Furthermore,
medications to be dispensed, could be tracked via the remote
computer 200, such that information identifying which medications
to access for which patient could be downloaded from the remote
computer 200 to the medication monitor 104. If single dosage
blister packs were utilized for medication dispensation, a further
cheek could, be incorporated through the association of a patient
with a specific room having a specific fixed receiver in addition
to the nurse's medication monitor 104, such that accessing
medication in a room for which the associated patient is not
indicated would result in the triggering of an alarm through, the
medication monitor 104, indicating that the nurse should verify the
medication, being dispensed in the room.
Passive RFID Capabilities
[0053] In addition to relying on an active circuitry using an
on-board power supply, the present invention may use a hybrid
system combining active and passive circuitry to assist in the
medication monitoring and dispensation. A passive system uses the
energy of radio frequency transmissions as a power source for
responding to a remote transmitter. The large advantage of a
passive system is that no on-board power supply is required. The
limitation is that the absence of an on-board power supply may
limit, the operation of monitoring circuitry when the RF
transmission is not sufficiently strong to power the circuitry.
Such a limit may also prevent the operation of a clock on the
instrumented medication package 102.
[0054] Passive RF circuitry is used in anti-theft RFID systems,
such that when the RFID tag is located within range of a RF
transmitter transmitting on the required frequency, the passive
RFID tag responds by transmitting an identification signal.
Typically, the limitation of RF signal strength as a power source
for the passive RFID limits a response to occurring when the RFID
tag is 3-5 feet from the RF transmitter. The circuitry within the
RFID may be hardwired such that software is not required in order
for the RFID chip to function. The RFID chip thus may function as a
circuit, rather than a general purpose computer executing
instructions.
Hybrid Passive and Active Circuitry
[0055] The limitation, of active monitoring capabilities inherent
in a passive RFID only equipped instrumented medication package may
be overcome by implementation of hybrid passive and active
circuitry on an instrumented medication package. FIG. 4 shows a
hybrid, instrumented medication package 400 utilizing both passive
RFID circuitry 402 for monitoring the package before the package is
dispensed, as well as active circuitry 404 for more specifically
monitoring the accessing of medication after dispensation. The
active circuitry 404 may be provided with a switch (not shown) for
connecting a power source to the circuitry, such as described in
applicant's U.S. patent application Ser. No. 10/234,021, titled
"Power Control for Instrumented Medication Package" and filed
herewith. The use of a switch to enable connecting the power source
406 at the time of dispensation allows the use of a smaller power
supply 406, as the power supply 406 does not need to provide energy
prior to the package being dispensed.
[0056] The passive circuitry 402 and active 404 circuitry may be
embodied in separate passive RFID and active RFID chips, with the
active RFID chip being provided with sufficient capabilities to
monitor times at which medication was accessed, times at which
medication was due to be taken, expiration dates, or environmental
sensors to monitor patient storage of the instrumented medication
package.
[0057] Such a hybrid active and passive system would allow
monitoring of the package while the package was in storage, such as
in a pharmacy area, as well as monitoring of the package while the
package was near a medication monitor. As discussed above, the
medication monitor could be communicably connected to a network to
allow dissemination of information received from the package to
relevant parties, or communication of information from relevant
parties to the package, such as to allow the downloading of
medication times, or an expiration date. As is evident from this
instruction, information such as medication times or expiration
dates would not need to be downloaded to the package at the time of
production, simplifying the task of providing requisite storage for
the information on the instrumented medication package.
[0058] The circuitry necessary to provide severable conductors 118
for each containment, for both the active circuitry and passive
circuitry, could be accomplished by utilising the same circuitry
for both aspects of the circuitry, or by providing redundant
severable conductors 118. Redundant severable conductors 118 could
be accomplished though the printing of multiple conductive layers
onto the package closure.
[0059] The ability of the RFH) chip to be hardwired allows the chip
to function without first requiring the chip to determine its
internal operating instructions. This capability may allow enhanced
monitoring of die contents of an instrumented medication package
102 to which passive RFID circuitry 402 is attached when, the
passive RFID circuitry 402 is combined with an instrumented
medication package 102. By integrating the severable conductors of
an instrumented medication package 102 into the circuitry of the
RFID chip, the circuitry of the severable conductors may be used to
form a portion of the RFID circuitry, such that a portion of a
response identifier generated by the passive RFID chip may be
determined by the condition of the severable conductors. This may
allow continuous monitoring of the severable conductors when the
instrumented medication package 102 is within the transmission
range of a requisite RF transmitter, without requiring an internal
power source. Although the integration of the severable conductors
118 with passive RFID circuitry 402 docs not provide for
monitoring, of times at which severable conductors 118 are severed
locally, it does allow an RF receiver associated with the RF
transmitter, (together embodied in a passive circuitry transceiver
404) to monitor the responding identification information, such
that the severing of a severable conductor 118 will change the
identification code transmitted by the passive RFID circuitry 402,
allowing a central station (not shown) receiving information via
the Passive Circuitry Transceiver 404 to detect the severing of a
severable conductor 118 within an instrumented medication package
incorporating passive RFID circuitry 404.
[0060] As theft of medications is an important issue in hospital
pharmacies, the incorporation of such a system into a hospital,
pharmacy may allow accessing of medication within the range of a RF
transmitter/receiver pair to be detected when medications are
accessed within a pharmacy. Such a capability may be used to reduce
the unauthorised access to controlled substances, such as pain
killers, since the accessing of medication within a containment may
be rapidly communicated to the RF transmitter/receiver pair. Thus,
control of the medication contained within an instrumented
medication package may be monitored when the instrumented
medication package is within a hospital pharmacy, allowing improper
accessing of controlled substances to be detected and responded
to.
[0061] A system embodying such a concept in a pharmacy environment
is show in FIG. 5. The hybrid instrumented medication package 400
may be equipped with a passive RFID circuitry 404 connected, to
severable conductors 118, such that the severable conductors 118
form a portion of the passive RFID circuitry 404. The passive RFID
circuitry may be installed on an instrumented medication package
502, such that the severable conductors 118 are multiplexed to
reduce the number of necessary leads. Power received by the passive
RFID circuitry may be applied to one end of each severable
conductor 118, with the severable conductors 118 functioning as
switches for generating an identification signal. For example,
considering the identification to be a digitally encoded
identification, where the passive RFID circuitry 404 receives power
from a severable conductor lead (indicating continuity of the
lead), the passive RFID circuitry 404 may transmit a 1, while where
no power is received, at the lead, the passive RFID circuitry 404
may transmit a 0. The passive RFID circuitry 404 may have a number
assigned, such as for example a product code for tracking purposes.
The passive RFID circuitry 404 would thus transmit the product
code, with the connector status code appended to the product code.
As an example, if a hybrid instrumented medication package 400 was
assigned a product code of decimal 2897 (binary 101101010001), and
had 12 containments, each with a severable conductor, if
containments 6 and 7 were open, the passive RFID circuitry 404
would transmit 101101010001000001100000 in response to a signal
received from a monitoring station 504 comprised of an RF
transmitter, an RF receiver, and a network connection.
[0062] In addition to the product code and status code, a unique
identifier for the specific hybrid instrumented medication package
400 may also be implemented. For example, the passive RFID
circuitry 404 may contain, a series of internal circuits that may
be originally continuous, but which may be broken through the
application of a voltage exceeding the capability of the circuit.
As such, die circuits may be selectively broken prior to the
passive RFID circuitry 404 being connected to an instrumented
medication package 102, in order to set a package specific code.
Alternately, Programmable Read Only Memory (PROM) may be
incorporated to allow programming of an identification into the
RFID circuitry. Either method allows mass-produced chips to be
customized based on an identity value. For example, using the above
binary coding, the package could be assigned a package specific
code of 101000010000 (or 1288 in base 10 numbering), such, that the
RFID would respond with 101101010001 101000010000 000001100000. The
signal need not be in binary form, but may rather use any of a
number of other forms, such as frequency modulation to reduce the
duration of a transmission, needed to transmit an identifier.
[0063] Additional, identification may be implemented as desired.
For example, rather man incorporating a specific package
identifier, the identifier may relate to a production hatch,
allowing identification of a production site, production date, or
lot shipping information. Alternate or additional information may
include the National Drug Code, expiration date, and/or a
manufacturer tracking identifier.
[0064] Deconflicting signals front a concentration of hybrid
instrumented medication packages, such as could occur where a
number of instrumented medication packages were stored in a
pharmacy area, may be accomplished through several methods.
[0065] Instituting a delay, such that an passive RFID circuitry
would respond only periodically, would reduce signal overlap, such
that the timing characteristics of a signal could be used to
distinguish the signal of one passive RFID circuitry from other
transmitting passive RFID circuitries. Alternately, transmission
frequencies could be varied to allow differentiation between
transmitting passive RFID circuitries.
[0066] A pharmacy area, or any other area where such monitoring is
desired, such as in a drug store or nursing station, may be
provided with an RF transmitter/receiver pair which is connected to
a network connection. The network connection may be communicably
connected to a central computer which stores information concerning
medications. The central computer 512 may additionally be
communicably connected, such as through a network 514, to a
dispensing input/output station 516 (hereafter "DI/O station"), to
allow a pharmacist to communicate dispensation of a hybrid
instrumented medication package 400 to the central computer 512.
Although, the DI/O station 516 is illustrated as a typical desktop
computer, the DI/O station 516 may be implemented in any device
which can be communicably connected to the central computer 512 to
allow a pharmacist or other entity dispensing medication from the
pharmacy area to communicate with the central computer 512. For
example, a personal digital assistant, provided with the relevant
operational capability, could be used. Such an embodiment could
additionally include an RF transmitter/receiver pair to allow a
specific instrumented medication package identifier to be
transmitted directly from a package to the DI/O station 516. The
central computer 512 may additionally be provided with a means for
indicating unauthoriised accessing of a medication to a responsible
third party; such as a security input/output (hereafter "SI/O
device" 518). The SI/O device 518 could, simply be a printer which
prints out administrative reports regarding the status of
instrumented medication packages, or could be a computer assigned
to a group responsible for monitoring the unauthorized accessing of
medications, such as a security group.
[0067] Use of such an instrumented medication package in the
pharmaceutical system described, is shown in, the process
illustrated in FIG. 6. Once an instrumented medication package was
placed into the pharmaceutical area, the RF transmitter would
transmit sufficient energy to generate a response by the RFDD chip.
The transmitted response would be received by the RF receiver, and
communicated to the network connection. The network connection
would then forward, the transmitted information to the central
computer. The central computer could then verity the status of the
instrumented medication package by parsing the identification
information received. The product code and package code portions of
the identifier could be used to update an inventory list for the
pharmacy area at which the identifier was received. The received
status code could be tested to determine whether the status of the
individual connectors bad changed in transit, such as if medication
was improperly accessed in transit. If a status change were
detected, the central computer could notify the appropriate
authorities, such as via a SI/O device as described above. The
status of the package would continue to be monitored while the
instrumented medication package was stored in the pharmacy area. As
such, should medication, contained in the package be accessed
improperly, the access would be detected, such that the improper
accessing could be attributed, to the person, improperly accessing
the package.
[0068] Tracking of the instrumented medication package could be
discontinued once the instrumented medication package was
transferred from the pharmacy area, or if the instrumented
medication package was dispensed. Information regarding such,
transfer or dispensation could be provided to the central, computer
via the DI/O station, such that the central, computer could account
for dispensation into a patient's bill, or monitor transfer to
ensure that a package reached a transfer destination. Should
medication, be accessed during transit, the accessing would, be
detected once the medication package reached its destination, such
that the task, of identifying who accessed, the medication would be
limited to those responsible for the transfer.
Combined Process
[0069] The present invention may be embodied in a process
integrating an instrumented medication package within a health care
system, as shown in FIG. 6. In order to provide for security
tracking of a hybrid passive and active IMP (hereafter referred to
as a "HIMP") stored within a pharmacy area, a passive monitor or
monitors may be located 602 in the pharmacy area. The locating 602
of the passive monitor may allow passive circuitry indicating the
presence of HIMP to be activated by the passive monitor, through
the passive monitor transmitting 606 and trigger signal which
causes a response 608 from the HIMP indicating the identity and
containment states of the HIMP. The passive monitor is preferably
communicably connected with a central computer, such that the
central computer can coordinate information associated with the
HIMP, as well as with, involved physicians, patients, pharmacists,
and/or other individuals or entitles involved in the healthcare
process.
[0070] A HIMP will typically be delivered 604 to a pharmacy area as
part of a restocking evolution. The HIMP may be transported from a
prior holding area, such as a pharmaceuticals storage area, or from
the pharmaceuticals manufacturer. Data and information concerning
the HIMP may typically be maintained by the entity storing the HIMP
prior to delivery to the pharmacy, such that a record as to the
status of containments within the HIMP may be made available to or
transferred to the central computer. This data may form a baseline
for status monitoring by the central computer.
[0071] As part of normal monitoring, the passive monitor may
transmit 606 a trigger signal to which the HDVIP is responsive,
generating a response 60S from the passive circuitry contained on
or in the HIMP, if the trigger signal is particular to a HIMP, the
central computer may forward an instruction to the passive monitor
to generate the trigger signal to detect the particular HIMP. For
example, where a pharmaceutical manufacturer was shipping a
quantity of medication contained in HIMPs to the pharmacy area, the
pharmaceutical manufacturer could inform the central computer in
advance of the pending shipment, as well as the specific trigger
signal information associated with the HIMPs, as well as
information concerning stains of the containments within the HIMPs.
Such information could be contained as part of routine invoicing
documents generated in response to an order for medication.
[0072] In response to the trigger signal, the HIMP could transmit
606 with an identifier and containment status. Containment status
may be of particular import where the medication contained in the
HIMP is a controlled substance, such as a pain killer. This
response would be received 610 by the passive monitor, informing
the passive monitor of the presence and status of the HIMP.
[0073] If the passive monitor does not detect 610 a response from
the BLIMP, the central computer may be informed 612 of the lack of
a response. A lack, of a response may indicate that the HIMP has
been removed from the pharmacy area, or is out of range of the
passive monitor. Either way, the pharmacy may likely have an
interest in investigating the lack of a response to ensure that the
HIMP, and the medication contained therein, is not missing.
Alternately, where the passive monitor is merely responsible for
forwarding received responses, the determination that a response
that should have been received was not may be made by the central
computer. In such a case, the central computer would track the
inventory of the pharmacy. When a HIMP is recorded as having been
delivered to the pharmacy area, the central computer would monitor
for responses forwarded from the passive monitor. If no responses
were received, the central computer could institute actions as
desired, such as notice to a pharmacist to verify the presence of
the HIMP in the pharmacy area, or instructions to security to
determine the location and status of the HIMP.
[0074] If the passive monitor detects 610 a response, the passive
monitor may forward 614 the received response to foe central
computer. The form of the response may be determined by the manner
chosen of distributing monitoring responsibilities. If all
processing is to be accomplished by the central computer, the
passive monitor may merely relay the response from the HIMP to the
central computer. If the passive monitor is assigned processing
tasks, such as testing the reported status of containments against
a prior status to detect changes, the passive monitor may only
report a "no change" report for a particular HIMP. Such
distribution of tasking may be dependant upon the architecture
chosen to implement the central computer, passive monitor, and the
communications connection between them. Accordingly, the form of
the response may even be a non-transmission, in the case of a
protocol reporting only changes in status. The response of the
central computer 616 is discussed further below.
[0075] The passive monitor may continue to monitor the HDVIP until
it is determined 618 that the package has been dispensed from the
pharmacy. Once it has been determined that the package has been
dispensed, the central computer may be informed 620 that the
package has been dispensed. Such information may be determined
through a pharmacist or other dispensing entity entering
information into a computer or network device. Alternately, a
separate monitor may be implemented at a portal through which
medication is dispensed, such that the portal monitor may detect a
response from passive circuitry passing within range of the portal
monitor.
[0076] As is evident from the potential, use of such a portal
monitor, additional monitors can be used at access points for the
medication storage areas, allowing a delivery monitor to detect
HIMP's being delivered, as well as HIMP's being dispensed. The use
of the severable conductors 118 as a portion of the circuitry
responsible for generating an identification response may allow
additional security, in that removal of the circuitry forming the
monitoring and response circuitry, such as when such circuitry is
implemented through a chip attachable to a medication package
having the requisite severable conductors, would prevent the HIMP
from responding correctly to a monitor in the storage area.
[0077] The process associated with the central computer monitoring
a HIMP stored in a storage area is shown in FIG. 68. When the
central computer is informed 604 of the delivery of a HIMP, such as
when the HIMP is delivered, the central computer may access 622
records, such as those previously stored, or such as provided by a
pharmaceutical manufacturer or an entity responsible for
transferring the medication, to receive a record regarding the
condition of the HIMP. Initially, the central computer may presume
the HIMP to be complete, such that the status of the severable
conductors is initially assumed to be connected. For example, where
8 containments am included in the HIMP, and a 1 in the relevant
position of the identification response indicates that a severable
conductor has not been broken, the central computer can use 1111
1111 as the presumed identifier response, and base the generation
of a notice upon the detection of a deviation from this code.
[0078] The central computer may compare 624 the status of the
containments by comparing the status portion of the identifier
code, such as by subtracting the previously stored code from the
received code, and generating an alarm for any non-zero result. If
a change in status is detected 626, the central computer may
evaluate and generate 628 a notice to have the change in status
evaluated by an entity responsible for the security of the HIMP.
For example, a hospital administrator may be informed, allowing the
hospital administrator to manually verify the condition of the
HIMP. The simple notice function alone may assist. In reducing
unauthorised accessing of medication, since persons responsible for
the unauthorised access would be aware of the ability of the
hospital administration to detect the unauthorized access in such a
timely fashion as to associate the unauthorized access with
individuals in the area where the unauthorized access takes place
through the timely detection of the unauthorized access. Upon
completion of the evaluation of a received status identifier, the
central computer may also update 630 a database storing information
on the HIMP, such as to record the stains at the recorded time to
allow tracking of when an access or unauthorized access
occurred.
[0079] As shown in FIG. 6C, the administrative aspects of a
physician prescribing medication may be integrated with the
dispensing of an instrumented medication package to reduce the
administrative tasking associated with prescribing the medication.
This involvement may begin by the physician informing 632 the
central computer of the prescription, potentially including dosing
and scheduling information as may be typical of prescriptions. The
central computer may then forward 634 the prescription information
to a pharmacist, who can pull 636 the prescribed, medication from
the pharmacy storage area, lire pharmacist may then associate 638
the specific instrumented medication package with the prescription
prior to dispensing 640 the medication, such as by informing the
central computer of the specific package number of the instrumented
medication package being dispensed. The pharmacist may also enable
active circuitry, such as by charging or recharging a power supply
associated with the instrumented medication package, or by
switching the package on if a switching capability is provided.
Such a transition may also include disabling of the passive
circuitry to prevent the passive circuitry from being mad now that
the package is associated with a particular package, and thus to
some extent provides private patient information. As noted above,
the pharmacist may inform 642 the central computer of the
dispensation, such that a central database tracking medication
information and patient records can be updated. Upon receipt of
such notification, the central computer may also update 644 the
inventory of the pharmacy, assisting in the replenishment of
pharmacy stocks.
[0080] FIG. 6D shows a process according to the present invention
involving an instrumented medication package associated with a
patient to whom the package has been dispensed, illustrating the
interaction between the patient and the data available from use of
the instrumented medication package. Initially, the patient
receives 646 the instrumented medication package. The patient may
need to associate the instrumented medication package with a
medication monitor, or the central computer may inform the
medication monitor of the association with the instrumented
medication package. The medication monitor may then access 648
background information associated with the particular instrumented
medication package and medication contained therein. The background
information may be instructions and warnings regarding the
medication, notices regarding how the medication should be taken,
or what activities should be curtailed while the medication is
being taken. Such information may be displayed to the patient by
the medication monitor, such as when a display or speaker is
provided on the medication monitor. A monitoring schedule may be
provided 650 to the medication monitor. The monitoring schedule may
be dependant upon factors associated with the particular
medication, such as the degree of adverse impact due to late taking
of the medication by a patient, or the frequency with which the
medication should be taken. The monitoring schedule may also be
related to an intake schedule, such that the medication monitor
would query the associated instrumented medication package to
determine whether medication had been taken on time, based on the
time when the medication was to be taken. The monitoring schedule
does not need to be fixed or periodic, hut may be varied as
required. For example, where no access to medication is detected at
a scheduled intake time, the periods between repeat queries may
decrease the longer the time past the scheduled intake time.
[0081] An intake schedule 652 may be provided to the medication
monitor to assist in providing information to a patient taking a
medication, such as through providing alarms when a scheduled
dosage has been missed, or through being able to acquire and
display for a patient information regarding adverse consequences of
not following an intake schedule. Such an adverse consequence
display could, for illustration purposes, inform the patient that
the effectiveness of a course of medication is reduced by 25% when
the intake schedule is not met, or that the likelihood of the
medical condition developing a resistance to the medication
increases by 25% when the intake schedule is not met.
[0082] The intake schedule may then be monitored 654 to assist a
patient in following the intake schedule. It may not be desired to
tie the monitoring schedule to the intake schedule such that
information request transmissions are made in accordance with the
intake schedule. If a medication is amenable to misuse, such as by
taking the medication too fast, a patient taking medication before
a scheduled intake time would not be detected in a timely fashion
by queries generated only at intake times. Accordingly, the intake
schedule may be a factor in the monitoring schedule, but may not be
controlled by the intake schedule.
[0083] If an intake time arrives without a patient accessing a
requisite containment 656, the medication monitor may generate 658
a signal to the patient that medication is due to be taken. The
signal can be an audible, tactile, or visual display indicating to
the patient that a scheduled intake event has been missed. For
example, a buzzer or vibrator associated with the medication
monitor may be actuated, with the signal not ceasing until manual
intervention by the patient. As a medication monitor may not be
continuously in contact with a patient, a buzzer or bell provides a
greater physical range over which a signal can be received by a
patient, while the use of a buzzer allows a quiet mode, such as if
a patient is in a business setting where a buzzer or bell would be
offensive.
[0084] The medication monitor could continue to monitor 660 the
instrumented medication package in accordance with the monitoring
schedule if data were received from the instrumented medication
package, the data could be forwarded 664 to the central computer.
The central computer could make this information available to a
physician responsible or the medical care of the patient, to a
pharmaceutical manufacturer or regulatory authority collecting data
on the patient's compliance with the intake schedule, or to other
entities involved in the healthcare process.
[0085] Instructions could also be transmitted 662 from the central
computer to the medication monitor. Such instructions could alter
the intake schedule, the monitoring schedule, or provide
information for a patient associated with the medication monitor.
For example, a patient could telephone a physician regarding
complications associated with the taking of a medication. The
physician could adjust the intake schedule for the medication, by
informing the central computer of the changed intake schedule. The
changed intake schedule could be transmitted from the central
computer to the medication monitor, which could then prompt a
patient associated with the medication monitor in accordance with
the changed intake schedule. Alternately, a physician could have
information regarding a complication forwarded to the medication
monitor for display to the patient, if the instructions received
were patient instructions 668, the patient could be signaled 670,
such as through an audible, tactile, or visual signal and the
instructions displayed for the patient on the medication monitor.
The provision of the instructions through the medication monitor
could also be used to document transmission to and receipt of the
instructions by the patient, such as by having the instructions
remaining displayed on the medication monitor until a patient
indicates understanding of the instructions.
[0086] Finally, if the medication monitor had been provided with
information regarding the total number of medication containments
included in an instrumented medication package, the medication
monitor could monitor the number of medication containments
remaining unaccessed to determine whether the HIMP was finished
672, and inform 674 the central computer when the medication
package had been completed, or inform the central computer in
advance of completion of the medication in the medication package
to allow a refill to be prepared.
[0087] As is evident from the above description, the present
invention may be embodied in other specific forms than the
embodiments described above without departing from the spirit or
essential attributes of the invention. Accordingly, reference
should be made to the appended claims, rather than the foregoing
specification, as indicating the scope of the invention.
* * * * *